Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Trading 09-19 12:37:56 EDT

0.1327

-0.0063

-4.53%

High0.1538	Low0.1207	Vol17.93M
Open0.1530	D1 Closing0.1390	Amplitude23.81%
Mkt Cap2.22M	Tradable Cap1.43M	Total Shares16.70M
T/O2.43M	T/O Rate166.10%	Tradable Shares10.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":0.1327,"timestamp":1726763852810,"preClose":0.139,"halted":0,"volume":17925700,"delay":0,"floatShares":10792000,"shares":16696571,"eps":-7.849832,"marketStatus":"Trading","change":-0.0063,"latestTime":"09-19 12:37:56 EDT","open":0.153,"high":0.1538,"low":0.1207,"amount":2429531.964665,"amplitude":0.238129,"askPrice":0.139,"askSize":2500,"bidPrice":0.1315,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-7.849832,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1726776000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.139,"preHourTrading":{"tag":"盘前","latestPrice":0.1511,"preClose":0.139,"latestTime":"09:29 EDT","volume":3721523,"amount":592612.97796051,"timestamp":1726752587766},"postHourTrading":{"tag":"盘后","latestPrice":0.14,"preClose":0.139,"latestTime":"19:58 EDT","volume":653943,"amount":90697.4586,"timestamp":1726703918302},"volumeRatio":17.20062},"requestUrl":"/m/hq/s/PBM/tweets","defaultTab":"tweets","newsList":[{"id":"2468579500","title":"BRIEF-Psyence Biomed Enters Into Agreement To Acquire Stake In Psylabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2468579500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468579500?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:41","pubTimestamp":1726749706,"startTime":"0","endTime":"0","summary":"Sept 19 (Reuters) - Psyence Biomedical Ltd   :   * PSYENCE BIOMED ENTERS INTO AGREEMENT TO ACQUIRE STAKE IN PSYLABS   * PSYENCE BIOMEDICAL: TO ACQUIRE 11.13% STAKE IN PRIVATELY-HELD PSYLABSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2468757375","title":"Psyence Biomedical to Acquire PsyLabs Stake From Psyence Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2468757375","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468757375?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:18","pubTimestamp":1726748315,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  said Thursday that it has entered into a conditional share sale agreement to acquire Psyence Group's 11.13% stake in privately held PsyLabs.Under the terms, Psyence Biomedical said it would issue shares worth $1.1 million, at $0.55 per share, to Psyence Group.The transaction is subject to several conditions, including the achievement of a pre-defined product development milestone by PsyLabs by Oct. 31, Psyence Biomedical said.PsyLabs produces psychedelics for use in research, clinical trials and drug development, according to Psyence Biomedical.Psyence Biomedical's shares rose more than 9% in recent Thursday premarket activity.Price: 0.1523, Change: +0.01, Percent Change: +9.57","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2468200995","title":"Psyence Biomed Enters Into Agreement to Acquire Stake in Psylabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2468200995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468200995?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:30","pubTimestamp":1726745400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA4HWMTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2468055520","title":"Press Release: Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2468055520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468055520?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:30","pubTimestamp":1726745400,"startTime":"0","endTime":"0","summary":"PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being. NEW YORK, Sept. 19, 2024  -- Psyence Biomedical Ltd.   today announced that it has entered into a conditional share sale agreement with Psyence Group   for the acquisition of an 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients  and extracts for use in research, clinical trials and drug development . Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at $1.1 million dollars, at a price of $0.55 per share, in exchange for Psyence Group's 11.13% stake in PsyLabs.Tony Budden, Chief Executive Officer of PsyLabs, said, \"As health regulatory agencies tighten the standards for psychoactive compounds, especially for Phase III trials and commercial production, purity is becoming a key factor for success in psychedelic drug ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4125","PBM","AUD","NQmain"],"gpt_icon":0},{"id":"2468816345","title":"Psyence Group's Nasdaq-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2468816345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468816345?lang=en_us&edition=fundamental","pubTime":"2024-09-18 21:30","pubTimestamp":1726666200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nTUA5WG4Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2468458196","title":"Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2468458196","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468458196?lang=en_us&edition=fundamental","pubTime":"2024-09-18 21:30","pubTimestamp":1726666200,"startTime":"0","endTime":"0","summary":"Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/18/2948301/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomed-Issues-Shareholder-Update-Recapping-Recent-Progress-and-Previewing-Key-Upcoming-Data-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4097","MNQmain","QID","IE00B3QW5Z07.USD","SQQQ","TQQQ","BK4588","BK4139","NDAQ","IE00BGHQF748.EUR","NQmain","PRGS",".IXIC","LU2065732104.USD","PBM","BK4585","BK4112","AUD","QLD","IE00BKPKM429.USD","LU2210150020.SGD","PSQ","LU2095319765.USD","BK4125","LU2210149790.SGD"],"gpt_icon":1},{"id":"2468358158","title":"Cigna's PBM Express Scripts Sues The FTC For Misleading Claims On The Industry In July Report -- MarketWatch","url":"https://stock-news.laohu8.com/highlight/detail?id=2468358158","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468358158?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:25","pubTimestamp":1726572300,"startTime":"0","endTime":"0","summary":"This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","FTC","ESRX","IE00B19Z3B42.SGD","BK4139","IE00BSNM7G36.USD","LU0289739699.SGD","LU0868494617.USD","LU1261432733.SGD","BK4588","LU1059921491.USD","IE0002270589.USD","PBM","BK4585","LU0058720904.USD","CI","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2468355842","title":"Cigna’s Express Scripts sues FTC over drug pricing report","url":"https://stock-news.laohu8.com/highlight/detail?id=2468355842","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468355842?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:23","pubTimestamp":1726572205,"startTime":"0","endTime":"0","summary":"Cigna's  pharmacy benefit manager  Express Scripts has filed a lawsuit against the Federal Trade Commission  over the agency's recent report on PBMs, which highlighted their contribution to soaring drug prices in the U.S. According to court documents submitted on Tuesday, Express Scripts has asked a federal judge in St. Louis, Missouri, to order the FTC to withdraw the report and recuse the agency's Chair, Lina Khan, from taking any action against the company. The report released in July detailed how the six largest PBMs control nearly 95% of all prescriptions filled in the U.S. through years of vertical integration and market concentration. In addition to Cigna's  Express Scripts, the report cited PBMs run by CVS Health , UnitedHealth , and Humana . The FTC released its findings as an interim report following a two-year investigation into PBMs' business practices.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/92183453/image_92183453.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/92183453/image_92183453.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4150249-express-scripts-sues-ftc-over-drug-pricing-report","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","LU0390134368.USD","PBM","FTC","LU0122379950.USD","LU0256863811.USD","IE0009355771.USD","IE00B19Z9P08.USD","BK4585","IE00B19Z9Z06.USD","BK4534","IE0002270589.USD","LU1571399168.USD","BK4550","IE00BJT1NW94.SGD","CVS","LU0208291251.USD","IE00B7SZLL34.SGD","IE00BN29S564.USD","LU0053666078.USD","SG9999014005.SGD","HUM","UNH","LU0187121727.USD","IE00BJJMRZ35.SGD","IE00B775H168.HKD","LU0061475181.USD","LU1093756325.SGD","LU0070302665.USD","LU0170899867.USD","LU0211326839.USD","LU0348723411.USD","LU0107464264.USD","IE00BKVL7J92.USD","LU0094547139.USD","LU0158827948.USD","IE00B1XK9C88.USD","LU0128525929.USD","LU0203345920.USD","BK4581","LU1699723380.USD","LU0097036916.USD","ESRX","LU0211327993.USD","IE00BSNM7G36.USD","IE00BZ9MQY76.HKD","LU0198837287.USD","LU0211326755.USD","CI"],"gpt_icon":0},{"id":"2468353888","title":"Express Scripts Sues FTC, Demands Withdrawal of PBM Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2468353888","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468353888?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:15","pubTimestamp":1726571700,"startTime":"0","endTime":"0","summary":"FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients. ST. LOUIS, Sept. 17, 2024 /PRNewswire/ -- In a lawsuit filed in federal court in Missouri, Express Scripts byEvernorth, a subsidiary of The Cigna Group, demanded that the Federal Trade Commission  retract its July 2024 report, which is filled with false and misleading claims about the pharmacy benefit management  industry and fails to serve the interests of American consumers.For more than two years, Express Scripts fully cooperated with the FTC study into the PBM industry, meeting the agency's extensive demands for data and information. The FTC's report disregarded the millions of documents and terabytes of data produced by Express Scripts and other PBMs. As a result, the report is riddled with false statements, misleading insinuations and violates the Commission's duty to follow due process and serve the public","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/20qO6aX8mqNR7IMq1wWz.Q--~B/aD0xMDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5ddaeba65247c499cec4830a77f645be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/20qO6aX8mqNR7IMq1wWz.Q--~B/aD0xMDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5ddaeba65247c499cec4830a77f645be"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/express-scripts-sues-ftc-demands-111500169.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/express-scripts-sues-ftc-demands-111500169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4139","BK4588","FTC","IE0002270589.USD","LU0058720904.USD","IE00B19Z3B42.SGD","ESRX","LU1261432733.SGD","BK4585","PBM","LU0868494617.USD","CI","IE00BSNM7G36.USD","LU1059921491.USD","IE00B19Z3581.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2468330003","title":"Cigna Sues FTC Over Agency's PBM Report -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2468330003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468330003?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:13","pubTimestamp":1726571580,"startTime":"0","endTime":"0","summary":"One of the country's biggest pharmacy-benefit managers, Cigna Group's Express Scripts, sued the Federal Trade Commission, demanding a retraction of a recent report critical of the companies that negotiate drug spending.In the lawsuit, Cigna's Express Scripts pharmacy-benefit unit calls the agency's July report \"seventy-four pages of unsupported innuendo\" and takes aim at FTC Chair Lina Khan, arguing that she is biased against the industry.The lawsuit, which the company filed Tuesday in federal court in St. Louis, heightens the conflict between the FTC and leading pharmacy-benefit managers, or PBMs, which play a critical role in paying for drugs.It comes after The Wall Street Journal reported the FTC is preparing to sue the largest PBMs over their tactics for negotiating prices for drugs including insulin.Andrea Nelson, chief legal officer of the Cigna Group, said the goal of the suit was to have the report retracted. The complaint asks the court to issue an order \"vacating and setting ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTC","CI","IE00BSNM7G36.USD","LU1261432733.SGD","IE00B19Z3B42.SGD","BK4196","LU0058720904.USD","BK4585","LU1059921491.USD","LU0289739699.SGD","LU0868494617.USD","BK4139","PBM","IE0002270589.USD","IE00B19Z3581.USD","BK4588"],"gpt_icon":0},{"id":"2467384395","title":"Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2467384395","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467384395?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:41","pubTimestamp":1726494060,"startTime":"0","endTime":"0","summary":"MORRISVILLE, N.C., Sept.  16, 2024  (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmona","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/16/2946755/0/en/Court-Finds-United-Therapeutics-Interference-with-Launch-of-Generic-Treprostinil-Injection-Caused-Losses-of-More-Than-137-Million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","PBM","LU1699723380.USD","UTHR","BK4007","LU1571399168.USD","BK4139","LQDA"],"gpt_icon":0},{"id":"2467848299","title":"Psyence Group's Nasdaq-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for Its Phase Iib Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2467848299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467848299?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:31","pubTimestamp":1726493481,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nTUAF8P7M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2467848758","title":"Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2467848758","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467848758?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:31","pubTimestamp":1726493460,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  16, 2024  (GLOBE NEWSWIRE) -- Psyence Group Inc (\"Psyence Group\") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","MNQmain","IE00B64PRP62.GBP","BK4585","SQQQ","BK4112","BK4588","IE00BGHQF748.EUR","QLD","BK4139","NDAQ","LU2210150020.SGD",".IXIC","LU2095319765.USD","TQQQ","QID","PSQ","NQmain","LU2210149790.SGD","IE00B3QW5Z07.USD","PBM"],"gpt_icon":1},{"id":"2467156819","title":"Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2467156819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467156819?lang=en_us&edition=fundamental","pubTime":"2024-09-16 19:30","pubTimestamp":1726486201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nTUA6RHHNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2467819440","title":"Press Release: Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2467819440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467819440?lang=en_us&edition=fundamental","pubTime":"2024-09-16 19:30","pubTimestamp":1726486200,"startTime":"0","endTime":"0","summary":"Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones. as a potential treatment for Adjustment Disorder in. IP licensing agreement with Psylabs for its botanical. It has been an eventful and productive few months since my last letter in March, and I wanted to take this opportunity to update you on our recent progress, as well as key milestones that we are focused on going forward.We also announced our second development indication, which will evaluate GMP nature-derived psilocybin as a potential treatment for Substance Use Disorders , including Alcohol Use Disorder . We plan to focus initially on AUD, and, to that end, we signed an agreement with Psylabs to be the exclusive supplier of highly purified psilocybin extract exclusively for these indications. SUDs represent a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUD","BK4139","LU2065732104.USD","BK4097","BK4125","PBM","PRGS","NQmain"],"gpt_icon":0},{"id":"2467308754","title":"Psyence Biomedical Faces Nasdaq Delisting Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2467308754","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467308754?lang=en_us&edition=fundamental","pubTime":"2024-09-14 05:27","pubTimestamp":1726262862,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd., a company developing psilocybin-based medicines, has been notified by Nas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-faces-nasdaq-delisting-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-faces-nasdaq-delisting-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SQQQ","BK4139","PSQ","LU2095319765.USD","NDAQ","IE00B64PRP62.GBP","MNQmain","LU2210149790.SGD","QLD","BK4588","IE00B3QW5Z07.USD","BK4112","PBM","TQQQ","LU2210150020.SGD","NQmain",".IXIC","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","QID"],"gpt_icon":1},{"id":"2467981038","title":"Psyence Biomedical receives delisting determination from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2467981038","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467981038?lang=en_us&edition=fundamental","pubTime":"2024-09-14 04:52","pubTimestamp":1726260748,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  said on Friday that it has received a letter from Nasdaq, notifying the company that it had not regained compliance with the Market Value of Listed Securities requirement for continued listing. Unless the company timely requests a hearing before a Hearings Panel, the company’s securities would be subject to suspension or delisting.  Psyence Biomedical  said it intends to timely request a hearing before the panel. The hearing request will automatically stay any suspension or delisting action pending the hearing.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/944274854/image_944274854.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/944274854/image_944274854.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4149739-psyence-biomedical-receives-delisting-determination-from-nasdaq","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","BK4139","SQQQ","PSQ","MNQmain","PBM","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","QID","QLD","IE00B64PRP62.GBP",".IXIC","BK4112","NQmain","TQQQ","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2467086742","title":"Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2467086742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467086742?lang=en_us&edition=fundamental","pubTime":"2024-09-14 04:30","pubTimestamp":1726259400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240913:nTUA5HXWML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2467089827","title":"Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2467089827","media":"GlobeNewswire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467089827?lang=en_us&edition=fundamental","pubTime":"2024-09-14 04:30","pubTimestamp":1726259400,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  13, 2024  (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Deter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/13/2946161/0/en/Psyence-Biomedical-Ltd-Announces-Receipt-of-Staff-Delisting-Determination-from-Nasdaq.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1543694498.USD","LU0320765646.SGD","LU1366192091.USD","LU0648001328.SGD","LU1162221912.USD","LU2210150020.SGD","BK4121","LU0106831901.USD","BK4139","A","LU0347712357.USD","PSQ","LU1165135440.EUR","IE00BGHQF748.EUR","LU2210149790.SGD","TQQQ","PBM","LU1201861249.SGD","LU0130102774.USD","LU2095319765.USD","LU1791807156.HKD","LU2462157665.USD","SQQQ","BK4567","BK4566","LU0052756011.USD","LU2092937221.SGD","NQmain","LU0098860793.USD","LU2413666699.HKD","IE00BKPKM429.USD","BK4207","LU0980610538.SGD","LU2417539215.USD","QID","LU1721428933.USD","LU0128525689.USD","IE00BSNM7G36.USD",".IXIC","BK4588","LU2236285917.USD","MNQmain","LU0130517989.USD","BK4112","LU2041044095.USD","BK4504","NDAQ","LU0477156953.USD","QLD"],"gpt_icon":1},{"id":"2466592229","title":"UnitedHealth Group's Guidance Is Overly Optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=2466592229","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466592229?lang=en_us&edition=fundamental","pubTime":"2024-09-12 14:39","pubTimestamp":1726123185,"startTime":"0","endTime":"0","summary":"Management's optimistic guidance is unrealistic given industry trends and the significant risk from PBM legislation impacting profitability.UnitedHealth's growth expectations are unsustainable at scal","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1169329578/image_1169329578.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1169329578/image_1169329578.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720610-unitedhealth-group-stock-guidance-overly-optimistic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4533","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0004445239.USD","IE00B2B36J28.USD","PBM","IE00B19Z8W00.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU0077335932.USD","BK4566","IE0009355771.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4534","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU0029864427.USD","LU0053666078.USD","UNH","IE00B19Z3B42.SGD","IE00B7KXQ091.USD","IE00BJJMRZ35.SGD","LU0187121727.USD","IE0005OL40V9.USD","IE00BJJMRY28.SGD","IE00B4JS1V06.HKD","BK4588","LU0211326839.USD","LU0079474960.USD","LU0107464264.USD","BK4532","LU0011850046.USD","BK4154","IE00BKVL7J92.USD","IE00B894F039.SGD","LU0094547139.USD","IE00B1XK9C88.USD","IE00BFSS8Q28.SGD","LU0128525929.USD","IE00B1BXHZ80.USD","LU0158827948.USD","LU0203345920.USD","LU0109391861.USD","IE0004445015.USD","LU0097036916.USD","IE00BFSS7M15.SGD","LU0211327993.USD","IE00BZ9MQY76.HKD","LU0211326755.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":-0.1804},{"period":"1month","weight":-0.7434},{"period":"3month","weight":-0.7683},{"period":"6month","weight":-0.8736},{"period":"1year","weight":-0.9875},{"period":"ytd","weight":-0.985}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0771},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.1811}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction